Galectin Therapeutics Inc. (GALT): Price and Financial Metrics
GET POWR RATINGS... FREE!
GALT Stock Price Chart Interactive Chart >
GALT Price/Volume Stats
| Current price | $1.16 | 52-week high | $2.57 |
| Prev. close | $1.13 | 52-week low | $1.02 |
| Day low | $1.12 | Volume | 65,400 |
| Day high | $1.18 | Avg. volume | 64,300 |
| 50-day MA | $1.18 | Dividend yield | N/A |
| 200-day MA | $1.51 | Market Cap | 69.14M |
Galectin Therapeutics Inc. (GALT) Company Bio
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company was founded in 2000 and is based in Norcross, Georgia.
Latest GALT News From Around the Web
Below are the latest news stories about GALECTIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GALT as an investment opportunity.
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology JournalStudy to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis.NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, “Machine Learning |
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisNORCROSS, Ga., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). NAVIGATE is the first study of its kind and is a global effort that recruited patients in 14 countries and on five continents. The m |
Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' NowGalectin Therapeutics Inc. (GALT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of StockholdersNORCROSS, Ga., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET. The Annual Meeting of Stockholders and webcast can be accessed via www.virtualshareholdermeeting.com/GALT |
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development SummitNORCROSS, Ga., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6th Obesity and NASH Drug Development Summit in Boston, MA. On November 30, 2022, Dr. Pol F. Boudes, Chief Medical Officer, will deliver a presentation titled “the challenges of developing drugs for NASH cirrhosis: the example of belapectin.” About Belapectin Belapectin is a complex c |
GALT Price Returns
| 1-mo | N/A |
| 3-mo | -11.45% |
| 6-mo | -46.79% |
| 1-year | -45.28% |
| 3-year | -55.89% |
| 5-year | -70.29% |
| YTD | 2.65% |
| 2022 | -45.41% |
| 2021 | -7.59% |
| 2020 | -21.68% |
| 2019 | -16.62% |
| 2018 | 2.69% |
Loading social stream, please wait...